NCT06141980View on ClinicalTrials.gov

Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes Mellitus

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
DRUG

DWP16001 0.3 mg

DWP16001 0.3mg, Tablets, Orally, Once daily

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY